Purdue Pharma Set to Forfeit $225 Million in Opioid Crisis Settlement

Tue Apr 21 2026 12:51:37 GMT+0000 (Coordinated Universal Time)

A federal judge is poised to finalize a significant settlement agreement with Purdue Pharma, obligating the company to pay $225 million. This settlement arises from Purdue's role in the opioid epidemic and ushers in a new phase for the bankrupt pharmaceutical giant.

Purdue Pharma, the maker of OxyContin, is expected to forfeit $225 million as part of a settlement related to thousands of lawsuits it faces over its involvement in the opioid crisis. The payment comes as the company endeavors to conclude its legal woes, with the Sackler family set to contribute up to $7 billion over the next 15 years to various government entities for opioid crisis mitigation. Critics stress that more accountability is needed for the Sacklers, who have faced no criminal charges despite the devastating impact of their products.

A federal judge is expected to sentence Purdue Pharma to forfeit $225 million to the Justice Department, paving the way for the completion of a settlement concerning the thousands of lawsuits the company is grappling with due to its actions during the opioid crisis.

This monetary penalty was established in a 2020 agreement intended to resolve both civil and criminal investigations the company faced. Should the judge approve the decision, Purdue will not be subjected to further penalties in exchange for settling the majority of these lawsuits.

After undergoing a protracted series of legal challenges, the settlement was sanctioned by a different judge last year and is anticipated to become effective by May 1. Under the terms, the Sackler family, owners of Purdue Pharma, must pay as much as $7 billion to various governmental bodies, including state, local, and Native American tribal governments, in addition to providing funds to some victims and their families.

The Sentencing's Long Road

Purdue Pharma pleaded guilty to three federal criminal charges in November 2020. The Connecticut-based company acknowledged its failure to implement an efficient program to prevent its potent prescription painkillers from being diverted to illegal markets, despite previously assuring the Drug Enforcement Administration of such measures.

They admitted to financing doctors through a speakers program to encourage prescriptions and compensating an electronic medical records company for distributing patient information that promoted opioid prescriptions.

While Purdue is on the hook to pay $225 million, the U.S. government conceded in their plea agreement to forgo collecting $5.3 billion in criminal forfeitures and fines and $2.8 billion in civil liabilities.

The Sacklers' Financial Contribution

The comprehensive settlement demands the Sackler family contribute a staggering $7 billion over 15 years, with a significant portion earmarked for initiatives to tackle the opioid crisis.

This settlement stands as one of the largest among various agreements involving drug manufacturers, distributors, and pharmacies, also representing the only significant accord that provides compensation to a subset of individual victims.

Calls for Individual Accountability

The Sackler family has been criticized for profiting from the opioid epidemic, amassing $10.7 billion from Purdue between 2008 and 2018, yet none have faced criminal charges.

Some victims' advocates lament that the settlement falls short of justice, especially given the connection of opioids to over 900,000 deaths in the U.S. since 1999. As the sentencing approaches, more than 54,000 individuals with claims against Purdue accepted the settlement, yet some victims' families are determined to continue pushing for individual prosecutions.

In their view, the funds from the settlement should address individual victims’ needs rather than be dispersed to governmental agencies that may not utilize them effectively in combating addiction.